Blinatumomab Approaches European Approval for MRD+ ALL

November 16, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of blinatumomab for the treatment of adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD) of at least 0.1%.The indication is specifically for patients with Philadelphia chromosome negative (Ph-), CD19-positive B-cell precursor ALL … (leggi tutto)